Evidence map›Paper›PMID 40681543›Full record

ArticleNature communications2025

Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M

Nita Patel, Asma Rehman, Jessica F Trost, Rhonda Flores, Zach Longacre, Mimi Guebre-Xabier, Haixia Zhou, Bin Zhou, Kelsey Jacobson, Desheng Jiang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nita PatelNovavax, Inc., Gaithersburg, MD, USA.
Asma RehmanNovavax, Inc., Gaithersburg, MD, USA.
Jessica F TrostNovavax, Inc., Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0003-0743-1228
Rhonda FloresNovavax, Inc., Gaithersburg, MD, USA.
Zach LongacreNovavax, Inc., Gaithersburg, MD, USA.
Mimi Guebre-XabierNovavax, Inc., Gaithersburg, MD, USA.
Haixia ZhouNovavax, Inc., Gaithersburg, MD, USA.
Bin ZhouNovavax, Inc., Gaithersburg, MD, USA.
Kelsey JacobsonNovavax, Inc., Gaithersburg, MD, USA.
Desheng JiangNovavax, Inc., Gaithersburg, MD, USA.
Xiaoyun BaiNovavax, Inc., Gaithersburg, MD, USA.
Rafia KhatoonNovavax, Inc., Gaithersburg, MD, USA.
Thomas KortNovavax, Inc., Gaithersburg, MD, USA.
James NortonNovavax, Inc., Gaithersburg, MD, USA.
M MadhangiNovavax, Inc., Gaithersburg, MD, USA.
Melinda HerseyNovavax, Inc., Gaithersburg, MD, USA.
Ann M GreeneNovavax, Inc., Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0003-4769-9288
Filip DubovskyNovavax, Inc., Gaithersburg, MD, USA.
Gale SmithNovavax, Inc., Gaithersburg, MD, USA. gsmith@novavax.com.ORCID http://orcid.org/0000-0002-6482-6026

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the recent rise in cases of highly pathogenic avian influenza (HPAI) A(H5N1) clade 2.3.4.4b infection in humans and animals, there is an associated increase in the risk of human-to-human transmission. In this study, we characterize a recombinant A(H5N1) A/American Wigeon/South Carolina/22/000345-001/2021 (A/AW/SC/2021) clade 2.3.4.4b vaccine. Purified recombinant A/AW/SC/2021 HA trimers formulated with Matrix-M

Indexed as

Antibodies, NeutralizingHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesNanoparticlesOrthomyxoviridae InfectionsAdministration, IntranasalAnimalsAntibodies, ViralFemaleHumansInjections, IntramuscularMiceMice, Inbred BALB CNanovaccinesAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNanovaccines

Identifiers

PMID40681543
PMCPMC12274490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.